BOSTON, Mass., May 27, 2026
Solu Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STX-0712, the company’s investigational therapy for the treatment of relapsed or refractory chronic myelomonocytic leukemia (CMML). The designation marks an important regulatory milestone for the clinical-stage biotechnology company as it advances the therapy through ongoing Phase 1 development for aggressive blood cancers with limited treatment options.
FDA Fast Track Designation Supports Accelerated Development
The FDA’s Fast Track program is intended to facilitate the development and expedite the review of investigational drugs designed to treat serious diseases and address significant unmet medical needs. The designation enables closer communication with the FDA throughout the development process and may help accelerate regulatory timelines if clinical results remain promising.
CMML is a rare and aggressive hematologic malignancy that shares characteristics of both myelodysplastic syndromes and myeloproliferative neoplasms. Patients with relapsed or refractory disease often face poor outcomes due to limited available therapies and high rates of treatment resistance.
According to Philip Vickers, President and CEO of Solu Therapeutics, the FDA recognition highlights the urgent need for more targeted therapies in CMML. He stated that STX-0712 has the potential to offer a highly selective approach by directly eliminating the malignant monocytes and bone marrow blasts that drive disease progression.
Advertisement
The company emphasized that Fast Track designation does not represent FDA approval but reflects the agency’s recognition of the therapy’s potential importance in addressing a serious medical condition.
STX-0712 Targets CCR2-Positive Cancer Cells
STX-0712 is built on Solu Therapeutics’ proprietary CyTAC™ (Cytotoxicity Targeting Chimera) platform, which combines the precision of small-molecule targeting with the therapeutic power of biologics to selectively eliminate disease-driving cells. The platform was exclusively licensed from GSK and is designed to create highly targeted therapies across oncology and immunology.
The investigational therapy targets CCR2, a G-protein coupled receptor highly expressed on malignant monocytes and bone marrow blasts associated with CMML and other blood cancers. By selectively depleting CCR2-positive cells, STX-0712 aims to reduce disease activity while minimizing effects on healthy non-malignant cells.
In addition to CMML, Solu Therapeutics is also evaluating the potential of STX-0712 in acute myeloid leukemia (AML) and other hematologic malignancies where CCR2-positive cell populations are believed to contribute to disease progression.
The company believes the selective cell-depletion strategy could represent a next-generation approach for treating difficult blood cancers that currently rely on toxic chemotherapy regimens with limited long-term effectiveness.
Ongoing Phase 1 Trial Advances Hematology Pipeline
Solu Therapeutics confirmed that an ongoing Phase 1 open-label multicenter clinical trial is currently evaluating STX-0712 as a monotherapy in patients with relapsed or refractory CMML and AML. The study is designed to assess safety, tolerability, dosing, pharmacokinetics, and preliminary anti-cancer activity.
The company plans to submit initial clinical data from the trial to a major hematology conference later in 2026, a milestone that could provide early insight into the therapy’s efficacy and safety profile.
Gene Solutions emphasized that SPOT-MAS 10 is intended to complement, not replace, guideline-recommended cancer screening methods. Patients receiving positive test results would still require physician-directed diagnostic confirmation based on predicted tissue of origin.
The Fast Track designation adds momentum to Solu Therapeutics’ growing oncology pipeline as competition intensifies in precision hematology and targeted cancer therapeutics. Industry attention continues shifting toward highly selective therapies capable of eliminating cancer-driving cells while reducing systemic toxicity and treatment-related complications.
As biotechnology companies increasingly focus on novel mechanisms for blood cancer treatment, STX-0712 and the CyTAC platform may position Solu Therapeutics as an emerging player in targeted hematologic oncology.
Source: Solu Therapeutics press release
